Nevertheless, the mechanism where progerin causes the widespread medical effects of HGPS has been unclear. To forge this hyperlink between molecular biology and medical end result, Tom Misteli, Ph.D., mind of the Cell Biology of Genomes Group at NCI’s Center for Tumor Analysis , and CCR staff scientist Paola Scaffidi, Ph.D., examined the effects of progerin on gene expression in a laboratory model of HGPS. They discovered that progerin activates genes involved in the Notch signaling pathway, a significant regulator of stem cell differentiation – – the procedure where stem cells bring about the mature cells that define different cells. Related StoriesFranziska Michor named recipient of NYSCF – Robertson Stem Cell PrizeUS and German researchers team up to advance quality control of individual stem cellsSCT, Thermo Fisher Scientific collaborate to progress development of cardiac disease modelsBecause the majority of the tissues affected by HGPS arise from a common developmental pathway, Misteli and Scaffidi looked at the effects of progerin on adult mesenchymal stem cells, the common cellular ancestor of the tissue types.Massaro, Ph.D., Donald E. Cutlip, M.D., Joseph P. Carrozza, Jr., M.D., Anthony D. Marks, M.D., Nancy Murphy, B.A., Iyah K. Romm, B.S., Madeleine Biondolillo, M.D., and Laura Mauri, M.D. For the MASS COMM Investigators: non-emergency PCI at Hospitals with or without On-Site Cardiac Surgery Since coronary balloon angioplasty was introduced into clinical practice in 1977, marked advances in technology, technique, adjunctive pharmacotherapy, and operator experience have resulted in higher rates of procedural success and lower rates of complications.1,2 Emergency coronary-artery bypass grafting , which was initially required in 6 to 10 percent of procedures,1,3 has become a rare event, with an incidence of 0.1 to 0.4 percent in contemporary studies.4-6 Moreover, as data helping the usage of primary PCI for sufferers with ST-segment elevation myocardial infarction have emerged, the need for timely access to the procedure has justified the growth of emergency PCI to hospitals that don’t have the capability for on-site cardiac surgery.7-9 Although there are limited data10,11 to support the practice of nonemergency PCI at hospitals that do not have the capability for on-site cardiac surgery, there is concern about the ratio of risk to benefit in this setting, as reflected in the class IIb recommendation in the 2011 PCI guidelines.12 The Cardiovascular Individual Outcomes Research Team Non-Major PCI trial, which was reported after publication of the 2011 PCI guidelines, directly compared the outcomes of PCI procedures between hospitals with on-site cardiac surgery and the ones without on-site cardiac surgery, in a prospective, randomized, controlled trial.13 PCI performed at hospitals without on-site cardiac surgery was noninferior to PCI performed at hospitals with on-site cardiac surgery regarding mortality at 6 weeks and the price of major adverse cardiac occasions at 9 months.